Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes

References

• Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088. doi: 10.1038/nrdp.2017.88.
   PubMed Web of Science ®Google Scholar
• Evans M, Lewis RD, Morgan AR, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33–43. doi: 10.1007/s12325-021-01927-z.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1–S127.
   PubMedGoogle Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;(Suppl):1–150.
   Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi: 10.1056/NEJMoa2025845.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi: 10.1056/NEJMoa2110956.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi: 10.1056/NEJMoa2204233.
   PubMed Web of Science ®Google Scholar
• American Diabetes, A. Introduction: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S1–S2.
   PubMedGoogle Scholar
• Folkerts K, Petruski-Ivleva N, Comerford E, et al. Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database. Mayo Clin Proc. 2021;96(4):975–986. doi: 10.1016/j.mayocp.2020.07.037.
   PubMed Web of Science ®Google Scholar
• Adhya J, Li C, Eisenmenger L, et al. Positive predictive value and stroke workflow outcomes using automated vessel density (RAPID-CTA) in stroke patients: one year experience. Neuroradiol J. 2021;34(5):476–481. doi: 10.1177/19714009211012353.
   PubMed Web of Science ®Google Scholar
• Assogba GFA, Couchoud C, Roudier C, et al. Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab. 2012;38(6):558–566. doi: 10.1016/j.diabet.2012.08.004.
   PubMed Web of Science ®Google Scholar
• National Diabetes Audit - 2015–2016: Report 1. Care Processes and Treatment Targets. 2017. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2015-2016-report-1-care-processes-and-treatment-targets
   Google Scholar
• Shen J, Huang Y-M, Song X-N, et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin Angiotensin Aldosterone Syst. 2016;17(3):1470320316656481. doi: 10.1177/1470320316656481.
   Web of Science ®Google Scholar
• Stempniewicz N, Vassalotti JA, Cuddeback JK, et al. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. Health care organizations. Diabetes Care. 2021;44(9):2000–2009. doi: 10.2337/dc20-2715.
   PubMed Web of Science ®Google Scholar
• Willison A, Tully V, Davey P. All patients with diabetes should have annual UACR tests. Why is that so hard? BMJ Qual Improv Rep. 2016;5(1):u209185.w3747.
   PubMedGoogle Scholar
• Groehl F, Garreta-Rufas A, Meredith K. The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease. Clinical Nephrol. 2023. doi: 10.5414/CN111106.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt K-U, Dorman NM, et al. Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Dis (Basel). 2020;6(5):309–317. doi: 10.1159/000509359.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 11 Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–S184.
   PubMedGoogle Scholar
• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17–28. doi: 10.1038/ki.2010.483.
   PubMed Web of Science ®Google Scholar
• NICE. Updated guide to the methods of technology appraisal. 2013.
   Google Scholar
• Consortium YHE. Delphi Method. 2016. https://yhec.co.uk/glossary/delphi-method/
   Google Scholar
• Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of delphi studies. J Clin Epidemiol. 2014;67(4):401–409. doi: 10.1016/j.jclinepi.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008–1015. doi: 10.1046/j.1365-2648.2000.01567.x.
   PubMed Web of Science ®Google Scholar
• Shardlow A, McIntyre NJ, Fraser SDS, et al. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: a primary care cohort study. PLoS Med. 2017;14(10):e1002400. doi: 10.1371/journal.pmed.1002400.
   PubMed Web of Science ®Google Scholar
• National Health Service England. 2019/20 National Cost Collection Data Publication 2021. Available from: https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/
   Google Scholar
• Shore J, Green M, Hardy A, et al. The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):387–395. doi: 10.1080/14737167.2019.1650024.
   PubMed Web of Science ®Google Scholar
• Kent S, Schlackow I, Lozano-Kühne J, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015;16:65. doi: 10.1186/s12882-015-0054-0.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854. doi: 10.1016/S2213-8587(19)30256-6.
   PubMed Web of Science ®Google Scholar
• NICE. NICE health technology evaluations: the manual. 2022. https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation
   Google Scholar
• Jesky MD, Dutton M, Dasgupta I, et al. Health-Related quality of life impacts mortality but not progression to End-Stage renal disease in Pre-Dialysis chronic kidney disease: a prospective observational study. PLoS One. 2016;11(11):e0165675. doi: 10.1371/journal.pone.0165675.
   PubMed Web of Science ®Google Scholar
• NICE. Chronic kidney disease in adults: assessment and management. 2015.
   Google Scholar
• Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7–11. doi: 10.1016/j.kisu.2021.11.003.
   PubMed Web of Science ®Google Scholar
• Gheith O, et al. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49–56.
   PubMedGoogle Scholar
• Garibotto G. A changing perspective for treatment of chronic kidney disease. J Clin Med. 2021;10(17):3840.
   PubMed Web of Science ®Google Scholar
• Burgos-Calderon R, Depine SA, Aroca-Martinez G. Population kidney health. A new paradigm for chronic kidney disease management. Int J Environ Res Public Health. 2021;18(13):6786.
   PubMed Web of Science ®Google Scholar
• Iroegbu C, Lewis L, Matura LA. An integrative review: chronic kidney disease awareness and the social determinants of health inequities. J Adv Nurs. 2022;78(4):918–928. doi: 10.1111/jan.15107.
   PubMed Web of Science ®Google Scholar
• Marion Kerr IHE. Chronic Kidney Disease in England: the Human and Financial Cost. 2012. https://www.england.nhs.uk/improvement-hub/wp-content/uploads/sites/44/2017/11/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf
   Google Scholar
• Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–484. doi: 10.1093/eurheartj/ehab777.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar